All In Biotech

Drug Trial Radar · NCT03921424

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Children Infected With Human Immunodeficiency Virus (HIV) (PNEU-WAY PED)

Last checked: Nov 19, 2026Latest source record: Jun 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 407 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

407

Actual

Start

Nov 5, 2019

Primary completion

May 3, 2021

Study completion May 3, 2021

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of V114 in children infected with HIV. Participants will be randomly assigned in a 1:1 ratio to receive either V114 or Prevnar 13™ followed 8 weeks later by a single dose of PNEUMOVAX™23. The primary objectives of this study are to evaluate the safety and tolerability of V114 in children 6 to 17 years of age inclusive infected with HIV and to evaluate the anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 30 days following vaccination with V114 or Prevnar 13™ by each vaccination group. There are no formal hypotheses.

Conditions

  • Pneumococcal Infections

Interventions

  • V114Biological

    15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.

  • Prevnar 13™Biological

    13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.

  • PNEUMOVAX™23Biological

    23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Solicited Injection-Site Adverse Event Following Vaccination With V114 or Prevnar 13™Time frame: Through 14 Days after Vaccination 1 (Up to Day 14)
  2. Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination With V114 or Prevnar 13™Time frame: Through 14 Days after Vaccination 1 (Up to Day 14)
  3. Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) Following Vaccination 1 (V114 or Prevnar 13™) or Vaccination 2 (PNEUMOVAX™23) Through Completion of StudyTime frame: Through 6 Months after Vaccination 1 (Up to Day 194)
  4. Anti-PnPs Serotype-specific IgG Geometric Mean Concentrations (GMCs) at 30 Days Following Vaccination With V114 or Prevnar 13™Time frame: Day 30

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • Perinatal HIV Research Unit ( Site 0042)

    Johannesburg, Gauteng, South Africa

  • Wits Reproductive Health and HIV Institute (WRHI) ( Site 0043)

    Johannesburg, Gauteng, South Africa

  • Family Clinic Research With UBUNTU ( Site 0045)

    Cape Town, Western Cape, South Africa

  • Be Part Yoluntu Centre ( Site 0041)

    Paarl, Western Cape, South Africa

  • CM Clinical Trial Unit-CM Clinical Trial Unit ( Site 0061)

    Chiang Mai, Thailand

  • Chulalongkorn University-Pediatrics ( Site 0062)

    Bangkok, Bangkok, Thailand

  • Faculty of Medicine Siriraj Hospital-Pediatric Infectious Diseases ( Site 0064)

    Bangkok, Bangkok, Thailand

  • Faculty of Medicine - Khon Kaen University-Pediatrics ( Site 0063)

    Amphoe Mueang, Changwat Khon Kaen, Thailand

  • Community Instit Dnipropetrovsk Municipal clinical Hospital #21 ( Site 0088)

    Dnipro, Dnipropetrovsk Oblast, Ukraine

  • Dnipropetrovsk Regional Center of Socially Significant Diseases ( Site 0082)

    Dnipro, Dnipropetrovsk Oblast, Ukraine

  • Odesa Regional Center of Socially Significant Diseases ( Site 0083)

    Odesa, Odesa Oblast, Ukraine

  • Vinnitsa Reg Cntr for AIDS Prevention-Control-Outpatient clinic dept ( Site 0086)

    Vinnytsia, Vinnytsia Oblast, Ukraine

  • Zaporizhzhya Regional Clinical Children's Hospital ( Site 0089)

    Zaporizhzhya, Zaporizhzhia Oblast, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.